Algorithms make it possible for companies to fix prices without explicitly coordinating with one another, posing a new test for regulators policing the market, said Lina Khan, chair of the Federal Trade Commission, during a media event hosted by KFF.
The U.S. Department of Justice has reportedly recently launched an antitrust investigation of UnitedHealth Group, which begs the question of whether the healthcare giant should be broken up. Experts have varying opinions.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Illumina has decided against further appeals of U.S. and European antitrust litigation challenging its acquisition of liquid biopsy company Grail. Illumina expects to have terms of the divestiture set by the end of the second quarter of 2024.
A group of labor unions have filed an antitrust complaint against UPMC. They alleged that the health system has prevented its workers from being able to advocate for themselves and their patients through “a draconian system of mobility restrictions and widespread labor law violations that lock in sub-competitive pay and working conditions.”
Combining the two companies may give UnitedHealth unfair access to its competitors data that is operated by Change Healthcare, the DOJ warned it its complaint, but a DC judge has blocked the complaint.
Attorney General Letitia James accused CVS of a scheme starting in 2017 to prevent New York safety net hospitals from using the company of their choice to obtain federal drug subsidies on prescriptions filled at CVS through the 340B program
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The Department of Justice filed the lawsuit in the U.S. District Court for the District of Columbia to stop the deal just ahead of it being finalized on February 27.
In both word and action, the Biden administration has ushered in an aggressive new era of antitrust enforcement. Less than a year in, administration leaders have rescinded previous antitrust guidelines, sometimes without explicit replacement, and stopped pending mergers dead in their tracks. It is difficult to cast judgment on so broad a policy shift, but […]
The companies have certified substantial compliance with a request for additional information from the Department of Justice, which opened an investigation of the merger in March. They struck an agreement with the agency not to merge until February of 2022, unless it drops its investigation before then.
Health systems filed two separate class action lawsuits against surgical robot maker Intuitive Surgical. They allege that the company used its market power to force them to sign restrictive repair contracts and buy replacement parts at high prices.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Sutter would pay $575 million, and would have to limit out-of-network costs and cease “all-or-nothing” contracting with health plans, according to the settlement.
Google announced it had closed its planned acquisition of Fitbit on Thursday, even thought the deal is still being investigated by the U.S. Department of Justice.
A federal grand jury indicted Surgical Care Affiliates, a network of surgical centers and hospitals owned by UnitedHealthcare, for agreeing with competitors not to poach top-level talent.
After European regulators signed off on the deal, Australian regulators rejected a proposal by Google to assuage concerns about its proposed acquisition of Fitbit. They will continue their investigation of the merger through the end of March.
The suit, filed Wednesday in federal court by more than four dozen attorneys general, accuses 26 generic drug companies and 10 executives of keeping prices artificially high for the drugs. It is the third in a series of antitrust lawsuits targeting the industry.